logo-loader
viewe-Therapeutics plc

e-Therapeutics continuing to convert business development into cash generating partnerships

e-Therapeutics PLC's (LON:ETX) Ray Barlow says they're actively engaged in exploring all organic and non-organic opportunities that have the potential to create incremental value for its shareholders.

He adds that multiple proposals for its artificial intelligence-based drug research products have been sent to potential partners and customers.

Quick facts: e-Therapeutics plc

Price: 3.07 GBX

AIM:ETX
Market: AIM
Market Cap: £8.26 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read